Leerink Partnrs Brokers Decrease Earnings Estimates for AVDL

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) - Research analysts at Leerink Partnrs cut their FY2026 EPS estimates for shares of Avadel Pharmaceuticals in a note issued to investors on Thursday, October 23rd. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $0.73 per share for the year, down from their prior forecast of $0.75. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals' FY2027 earnings at $1.23 EPS.

A number of other research analysts have also recently commented on AVDL. Jefferies Financial Group cut Avadel Pharmaceuticals from a "buy" rating to a "hold" rating and decreased their price target for the stock from $22.00 to $20.00 in a research report on Wednesday. Wall Street Zen upgraded Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 28th. Piper Sandler cut shares of Avadel Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Lifesci Capital lowered Avadel Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Finally, Needham & Company LLC lowered shares of Avadel Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday. Three research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Avadel Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $18.72.

Avadel Pharmaceuticals Price Performance

Shares of NASDAQ:AVDL opened at $18.56 on Friday. The company has a market capitalization of $1.80 billion, a P/E ratio of -618.67 and a beta of 1.46. Avadel Pharmaceuticals has a 1 year low of $6.38 and a 1 year high of $18.65. The business's 50 day simple moving average is $15.21 and its 200 day simple moving average is $11.50.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.08. The business had revenue of $68.13 million for the quarter, compared to the consensus estimate of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The firm's quarterly revenue was up 64.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Several large investors have recently bought and sold shares of AVDL. Wealth Effects LLC raised its position in Avadel Pharmaceuticals by 1.1% in the first quarter. Wealth Effects LLC now owns 2,369,122 shares of the company's stock valued at $18,550,000 after purchasing an additional 24,992 shares during the last quarter. Investors Asset Management of Georgia Inc. GA ADV grew its stake in shares of Avadel Pharmaceuticals by 16.4% in the first quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 139,975 shares of the company's stock worth $1,096,000 after purchasing an additional 19,700 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Avadel Pharmaceuticals by 4.0% in the first quarter. Bank of New York Mellon Corp now owns 234,120 shares of the company's stock worth $1,833,000 after purchasing an additional 9,025 shares during the last quarter. Pekin Hardy Strauss Inc. bought a new stake in shares of Avadel Pharmaceuticals in the first quarter worth $110,000. Finally, Iridian Asset Management LLC CT increased its stake in shares of Avadel Pharmaceuticals by 47.2% in the first quarter. Iridian Asset Management LLC CT now owns 249,586 shares of the company's stock valued at $1,954,000 after buying an additional 80,000 shares during the period. 69.19% of the stock is currently owned by institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.